Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG)

Inclusion Criteria:

* Written informed consent
* Age \>= 18 years
* Histologically confirmed diagnosis of squamous cell carcinoma of the penis
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
* Measurable disease criteria according to RECIST criteria (version 1.1)
* Progressive disease after treatment with cisplatin or carboplatin based chemotherapy.
* Archived tumor tissue must be provided for all subjects for biomarker analysis before and/or during treatment with investigational product.
* Adequate organ system function - Haemoglobin \>= 9.0 gr/dl (5.6 mmol/L) and stable in the previous 4 weeks to start study treatment - Neutrophils \>= 1.5 x 10\*9/L - Platelets \>= 100 x 10\*9/L - Total bilirubin \<= 1.5 x UNL - AST/SGOT and ALT/SGPT \<= 2.5 x UNL - serum creatinine \<= 1.5 mg/dL - Urine protein to creatinine ratio \< 1.
* Normal coagulation tests: - Prothrombin time (PT) or international normalized ratio (INR) \<= 1.2 X ULN - Activated partial thromboplastin time (aPTT) \<= 1.2 X ULN 10. Are able to swallow and retain oral tablets

Exclusion Criteria:

* Prior malignancy.
* Central nervous system metastases at baseline, with the exception of those subjects who have previously-treated CNS metastases (surgery ± radiotherapy, radiosurgery, or gamma knife) and who meet both of the following criteria: a) are asymptomatic and b) have no requirement for steroids or enzyme-inducing anticonvulsants
* Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding.
* Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product.
* Corrected QT interval (QTc) \> 480 ms
* History of any one or more of the following cardiovascular conditions within the past 6 months: - Cardiac angioplasty or stenting - Myocardial infarction - Unstable angina - Coronary artery bypass graft surgery - Symptomatic peripheral vascular disease - Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA)
* Poorly controlled hypertension \[defined as systolic blood pressure (SBP) of \>= 140 mmHg or diastolic blood pressure (DBP) of \>= 90 mmHg\].
* History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.
* Evidence of active bleeding or bleeding diathesis.
* Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels that increase the risk of pulmonary hemorrhage
* Recent hemoptysis (\>= 1/2 teaspoon \[2.5 mL\]) of red blood within 8 weeks before first dose of study drug).
* Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subjects safety, provision of informed consent, or compliance to study procedures.
* Unable or unwilling to discontinue use of prohibited medications 14 days prior to the first dose of study drug and for the duration of the study.
* Treatment with any of the following anti-cancer therapies: - radiation therapy, surgery or tumor embolization within 14 days prior to the first dose of pazopanib OR - chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy within 14 days prior to the first dose of Pazopanib
* Administration of any non-oncologic investigational drug within 30 days prior to receiving the first dose of study treatment
* Any ongoing toxicity from prior anti-cancer therapy that is \>Grade 1 and/or that is progressing in severity, except alopecia.
* Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib or paclitaxel and/or excipients that contraindicates their participation.
* Previous taxane or/and antiVEGF treatment would not allow patient to participate in the study.